Previous 10 | Next 10 |
A mere day after its stock rose by nearly 20%, biotech DBV Technologies (NASDAQ: DBVT) experienced a much stronger leap on Thursday. Shares of the company, which is developing a patch product to treat peanut allergies, ascended by nearly 80%. Still buoyed by the highly positive ...
Gainers: Power bridge Technologies (PBTS) +177%. Applied UV (AUVI) +50%. Cardiff Oncology (CRDF) +38%. DBV Technologies (DBVT) +28%. View (VIEW) +24%. Viracta Therapeutics (VIRX) +22%. Finger Motion (FNGR) +21%. Scien joy (SJ) +20%. Aero Clean Technologies (AERC) +19%. Akso Health Group (AHG)...
DBV Technologies (NASDAQ:DBVT) stock continued its rally on Thursday, adding ~28% to $2.31 in mid-day trading, after an 18.3% gain in the previous session. The company earlier in the day said that it was planning to raise $194M in gross proceeds via a private placement in ...
Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...
DBV Technologies (NASDAQ:DBVT) is planning to raise $194M in gross proceeds via a private investment in public equity (PIPE) financing. The company intends to sell ~32.86M ordinary shares, and pre-funded warrants to buy up to ~28.28M shares. The company said the ordinary shares will be sold a...
Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, today announced an aggregat...
Shares of the unique biotech DBV Technologies (NASDAQ: DBVT) surged nearly 20% higher on Wednesday, far outpacing many peer stocks. That's because the company had some very encouraging news to impart about its key pipeline drug. DBV is developing a patch treatment for peanut all...
Gainers: DBV Technologies (DBVT) +21%. Rubius Therapeutics (RUBY) +20%. Annovis Bio (ANVS) +17%. LumiraDx (LMDX) +16%. CTI BioPharma (CTIC) +15%. Losers: Rigel Pharmaceuticals (RIGL) -48%. Cosmos (COSM) -13%. Accelerate Diagnostics (AXDX) ...
Cyren (CYRN) +39% on €10M sale of secure email gateway unit. Redbox Entertainment (RDBX) +25%. DBV Technologies (DBVT) +19% phase 3 trial for peanut allergy treatment in toddlers meets main goal. Brenmiller Energy (BNRG) +16%. Energy Focus (EFOI) +15%. Aldeyra Thera...
3 Penny Stocks That Climbed in After Hours Trading After a mostly bullish day of trading penny stocks and blue chips, there is a lot for investors to know. Right now, we have to consider the main factors that are at play in the stock market. This includes rising inflation, and more impo...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...
Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45 th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa...
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 *...